Abstract
Rising costs continue to plague healthcare and mental healthcare. The latest variation of managed care techniques has been to try to reduce medication costs by instituting formulary restrictions. To date, the results have been spotty at best, with a suggestion of a ballooning of more general mental healthcare costs, as well as possibly worsening of quality of care. New challenges are looming in terms of the results of the CATIE study comparing typical and atypical antipsychotic medication, as well as the beginning of Medicare D medication coverage. In the midst of the uncertainty and complexity, the psychiatrist administrator has the ethical challenge and chance to make a major difference. By keeping the well-being of patients first, but also addressing the needs of the institution, payor, and other stakeholders, the psychiatrist administrator can ethically find ways to reduce costs and increase quality. One such product could be medication algorithms that also incorporate costs, side effects, and general healthcare.
Similar content being viewed by others
References
Sabin JE, Daniels N, Teagarden JR: The perfect storm. Psychiatric Annals 34:125–132, 2004.
Tennison CR: Responding to restrictive formularies. Psychiatric Annals 34:139–148, 2005.
Moffic HS: Managed behavioral healthcare poses multiple ethical challenges for clinicians. Psychiatric Annals 34:98–104, 2004.
American Psychiatric Association: The Principles of Medical Ethics with Annotations Especially Applicable to Psychiatry. Washington, DC, American Psychiatric Association, 2001.
Moffic HS: Ethical Principles for Psychiatric Administrators. American Association of Psychiatric Administrators Newsletter Summer:5–9, 2000.
Starkweather KK, Shon SP: Implementing Medication Algorithms: The Texas Experience. Psychiatrist Administrator 1(1):13–18, 2001.
Moffic HS: The Ethical Way: Challenges and Solutions for Managed Behavioral Healthcare. San Francisco, Jossey-Bass, 1997.
American Psychiatric Association Office of Healthcare Systems and Financing: Fail-First Policies – The Tip of the Pharmacy Benefit Management Iceberg 8(506):1&19, 20, 2002.
Sabin JE, Daniels N: Improving Psychiatric Drug Benefit Management: II. Kaiser Permanente's Approach to SSRI's. Psychiatric Services 54:1343–349, 2003.
Sullivan PW, Valuck R, Brixner DJ, et al: Managed Care's Response to a Pharmacoeconomic Model of Serotonin Reuptake Inhibitors. P&T 30:178–182, 2005.
Kanapaux W: Managed to hold down medicaid drug costs. Behavioral Healthcare Tomorrow April:22–29, 2005.
New Jersey Psychiatric Association: Consensus and Evidence Based Guidelines for Psychotropics in Formularies. http://www.psychnj.org/, May 10, 2005.
Ingoglia CS: Caring for persons with mental illness: making policy decisions that are truly cost-effective. Drug Benefit Trends Supplement 15:5–11, 2003.
Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al: Effects of limiting medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331:650–655, 1994.
Frieden J: Psychiatric Formularies Not Likely to Save Money. Clinical Psychiatry News December:64, 2003.
Cranor CW, Bunting BA, Christensen DB: The Ashville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. Journal of the American Pharmaceutical Association 43:149–159, 2003.
Wassef AA, Winkler DE, Roche AL, et al: Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions. American Journal of Psychiatry 162:330–339, 2005.
Ning A, Dubin WR, Parks JJ: Pharmacy costs: Finding a role for quality. Psychiatric Services 56:909–911, 2005.
Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209–23, 2005.
Keefe RSE, Seidman LJ, Christensen BK: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry 161:985–995, 2004.
Stahl SM: Detecting and dealing with bias in psychopharmacology. PsychEd Up 1(4):6, 2005.
Baker JG: Engaging community mental health stakeholders in pharmacy cost management. Psychiatric Services 52:650–653, 2001.
Siris SG: Minding my own business. Psychiatric Services 56:1339, 2005.
Fawcett J: What we need is living treatment algorithms. Psychiatric Annals 35:873, 2005.
Horn S: Limiting access to psychiatric services can increase total health care costs. Drug Benefit Trends Supplement 15:12–18, 2003.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moffic, H.S. Ethical Principles for Psychiatric Administrators: The Challenge of Formularies. Psychiatr Q 77, 319–327 (2006). https://doi.org/10.1007/s11126-006-9017-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-006-9017-8